

# Index

- 3+3 design, 6, 8, 9, 12
- $\alpha$ -trimmed mean, 504
- A+B designs, 6, 8, 11, 12
- A+B+C design, 12
- Absolutely continuous, 519
- Accelerated failure time (AFT), 160, 386
- ACTG 076 trial, 519, 520
- ACTG 364 study, 178
- Adaptive design, 28, 34, 45, 49, 63, 519, 520
  - continuous (CAD), 520
  - delayed responses in, 44
  - for allocation, 518
  - for categorical responses, 41
  - for continuous responses, 42
  - optimal, 43
  - Wilcoxon-Mann-Whitney-type, 43
- Adaptive estimation
  - in clinical trials, 508
- Adaptive procedure, 505
  - robust, 518
  - in clinical trials, 518
- Adaptive RPW, 40
- Additive hazards regression, 160
- Adherence, 84, 86, 87, 90, 92
- AIDS, 83, 90, 91, 92, 94, 124, 519
- Akaike information criterion (AIC), 538, 539
- Algorithm
  - cross-validation, 103
  - pool adjacent violators, 9
- Allocation designs
  - nonparametric-score-based, 42
  - link-function-based, 43
- Allocation rule
  - optimal, 44
- Analysis by allocation unit, 74
- ANOVA, 70, 71
- Anthropogenic, 123
- Antiretroviral (ARV)
  - agent, 85, 87
  - drugs, 87
  - therapy, 84, 85, 92
- Arrays. *See* Microarrays
- Array comparative genomic
  - Hybridization (aCGH), 385, 400
- Asymptotically measurable, 165
- Asymptotic bias, 504
- Asymptotics
  - increasing domain, 97
  - infill, 97
- Atlas methods, 125
- Atmospheric science, 136
- At risk, 100, 506
- Attenuation factor, 144
- Autocorrelation, 111
- Average sample number (ASN), 57, 60
- Autoregressive model
  - non-Gaussian, 529
- Autoregressive moving average (ARMA), 132

- Avian flu, 124  
AZT, 33, 34, 519
- Backfitting, 125  
Bandwidth, 101, 102, 103, 104, 107, 515  
Baseline hazard, 160  
Baseline integrated hazard, 162  
Baseline survival function, 159  
Bayes theorem, 9, 22, 113  
Bayesian  
  analytic methods, 84  
  approach, 23, 87, 94, 113, 115, 118, 529, 530, 542  
  computation, 168  
  deconvolution model (BDM), 531, 542  
  design, 11, 18, 28, 45  
  feasible designs, 10  
  hierarchical framework, 117  
  hierarchical nonlinear model, 87  
  information criterion (BIC), 529, 538, 539  
  kriging, 112, 113  
  methods, 18, 23, 24, 27, 28, 84, 125, 128, 169, 396, 448, 479  
  model averaging, 530  
  modeling approach, 89  
  nonlinear mixed-effect model, 87, 88, 90  
  paradigm, 18, 22, 49  
  point of view, 142  
  prediction, 90, 92, 94  
  procedure, 92  
  semivariogram, 115  
  statistics, 84, 118  
  techniques, 506  
Benefit time, 507  
Beta(a,b), 23  
Behrens-Fisher problem, 43  
Berkson error model, 141, 142, 144  
Bernoulli, 55, 56, 59  
Best linear unbiased prediction (BLUP), 108, 109  
Beta  
  distribution, 24  
  family, 23  
  function, 23  
Between-cluster correlation, 68, 69  
Between-cluster variance, 73  
Biased coin design, 45  
  doubly adaptive (DBCD), 39, 40  
Binary response, 143, 144, 149, 150, 152  
  bivariate, 142, 146  
  misclassified, 149  
Binomial, 19, 20, 22, 23, 24, 26, 56, 59  
  sampling, 57, 59, 131  
  spending function method, 21  
Biodiversity, 123  
Biomarkers, 309, 465  
Birth-and-death urn (BDU), 37, 38  
  with immigration (BDUI), 37, 38  
Birth processes, 41  
Block jackknife, 171  
BLUP, 111, 113, 117  
Boosting, 394, 444, 454  
Bootstrap, 160, 163, 164, 165, 166, 167, 169  
  likelihood, 166  
  log likelihood, 169  
  piggyback, 160, 168, 169  
  weighted, 168  
Breakdown point, 502, 504  
  asymptotic, 504, 505  
  finite-sample, 504  
Breslow estimator, 162  
Brownian bridge, 165  
Brownian motion, 165  
B-spline, 532, 533  
  cubic, 131  
 $\chi^2$   
  approximation, 125  
  test, 21  
Cancer, 143, 151, 152, 515, 548  
  incidence, 506  
  lifetime risk of developing, 549  
  recurrence, 506  
  remission, 506  
  screening, 507  
Carcinogenesis models, 547  
  biologically based, 548, 549  
  physiologically based pharmacokinetic (PBPK), 548, 549  
Case-control  
  sampling, 508  
  studies, 74, 405, 508, 509  
Cases  
  incident, 98  
  prevalent, 98

- Censored data, 351, 385
  - right, 160, 506, 513
  - survival, 513, 515
- Censoring
  - case I interval censoring, 160
  - current status censoring, 160
  - distribution, 515
  - induced dependent, 506
- Central limit theorem, 515
- Chemotherapy, 515
- Childhood leukemia, 100
- Cholera, 97, 123, 124, 128, 130, 131, 132, 134, 135, 136
- Class
  - age-structured, 124
  - exposed, 124
  - geographically structured, 124
- Classification, 328, 444, 450
  - error, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153
- CLUSTER, 529, 540
- Cluster
  - detection, 107, 119
  - size, 72
- Clustering, 328, 365
- Cluster randomization design, 73
- Cluster randomized trial (CRT), 67, 68, 69, 71, 72, 73, 74, 75, 76
- Coefficient of variation, 73, 152, 529
  - between-cluster, 73
- Cohort, 8, 74, 143, 151, 152
- Colored noise, 132
- Comparative
  - phase II clinical trial, 23
  - studies, 17, 23
- Compartment model, 124, 130
  - Susceptible-Infected-Removed (SIR), 124
- Competing-risks data, 506
- Completely randomized design, 71
- Conditional independence, 147
- Conjugate prior, 23
- Consistent and asymptotically Normal (CAN), 134, 162, 508, 515
- Contagion processes, 100
- Contamination, 506, 507
  - infinitesimal, 504
- Continual reassessment method (CRM), 6, 10, 11, 12
- Continuous-time
  - disease models, 125
  - models, 125, 136
  - processes, 124, 125
- Contour plot, 116
- Control theory, 125
- Cook's statistic, 513
- Cortisol (hydrocortisone), 528
- Covariance function, 110, 113, 114, 118
  - exponential family of, 114
  - isotropic, 114
  - stationary, 114
- Cox model, 159, 160, 169, 171
  - for current status data, 161
  - for right-censored data, 160
  - partly linear, 161
- Cox partial likelihood, 171
- Cox proportional hazards
  - model, 169
  - regression, 386
- Cramer-von Mises procedure
  - weighted, 509
- Cross-contamination, 72
- Cross-resistance patterns, 86
- Cross-validation algorithm, 103
- Cumulative cohort design, 7
- Current status data, 160
- Cycle detector, 529
- Cytostatic drugs, 27
- Cytotoxic
  - anticancer drugs, 27
  - treatments, 27
- Data assimilation, 136
- Death processes, 41
- Decay function
  - exponential or bi-exponential, 530
- Decision-theoretic
  - design, 18
  - paradigm, 18
- Deconvolution, 528, 531, 532
  - Veldhuis-Johnson model, 529
- Delay-adjusted procedure, 45
- Demographic variability, 131
- Density power divergence, 514
  - estimating equation, 514, 515
  - estimator that minimizes, 514

- Depression
  - clinical, 46
  - endogenous, 46
- DerSimonian-Laird procedure, 508
- Design
  - adaptive, 28, 34
  - Bayesian, 9, 11
  - biased coin, 34, 45
  - cluster randomized, 68, 73
  - completely randomized, 71
  - continuous drop-the-loser, 43
  - cumulative cohort, 9
  - doubly adaptive biased coin, 39, 40, 44
  - dose escalation, 16
  - drop the loser with covariate, 41
  - effect, 72
  - escalation with overdose control, 10
  - link-function-based allocation, 43, 63
  - matched-pair, 71
  - nonparametric-score-based allocation, 42
  - optimal adaptive, 43
  - partial sequential, 59
  - stratified design, 71
  - success-driven, 62
  - Wilcoxon-Mann-Whitney-type adaptive (WAD), 43
- DETECT, 529
- Deviance, 508
- Dichotomous response, 518, 519, 520
- Differential equations, 84, 85, 87, 90
  - nonlinear, 84
  - ordinary (ODE), 131, 132
  - stochastic (SDE), 131, 132
- Differential expression. *See* Microarrays
- Dioxin, 108, 109, 111, 113, 114, 115, 116, 117, 118
- Directional derivative, 503
- Discrete-time
  - mechanistic modeling, 125
  - models, 124, 125
  - nonlinear systems, 125
- Disease
  - dynamics, 123, 124, 135
  - prevalence, 123
- Distance-decay correlation function, 116
- Distribution
  - binomial, 8, 511
  - bivariate normal, 146, 147
  - Gaussian/normal, 97, 118, 144, 148, 519
  - generalized gamma family of, 529
  - multivariate normal, 118
  - Poisson, 100
  - spatial, 97
  - two-cell Bernoulli, 511
  - Weibull, 515, 516
- Distribution-free test, 508
- Divergence
  - density-based, 513
- Dixon-Mood decision rule, 7
- Dominating measure, 513, 514
- Donsker class, 164, 165
- Dose escalation design, 16
- Dose finding, 6
- Dose-limiting toxicity, 6
- Dose-response, 152
  - model, 7
  - relationship, 548
- Dose-response function
  - isotonic estimates of, 6
- Dose-toxicity models, 9
- Dose-toxicity relationship, 6
- Dosimetry, 143, 151
- Double-blind, 16
- Drop-the-loser (DL), 41, 42, 48
  - continuous (CDL), 43, 47, 48
  - design with covariate (DLC), 41
  - for binary responses, 63
  - urn, 37, 38
- Drug
  - efficacy, 84, 85, 87
  - exposure, 86, 87
  - holiday, 94
  - resistance, 83, 87, 94, 124
  - susceptibility, 84, 85
- Durham-Flournoy theorem, 7, 8
- Dynamic
  - models, 83, 84
  - multiprocess linear model, 529
  - predictions, 94
- Dynamical systems
  - nonlinear, 124, 137
  - partially observed, 136
  - stochastic, 136
- Ecological, 136
  - application, 126
  - model, 125, 128

- Ecology, 124
- Economics, 125
- Edge effect, 105
- Effective range, 111, 114, 116
- Efficiency, 125, 153, 162, 502, 507, 515, 519
- Elimination function  
  exponential or bi-exponential, 530
- Elliptical contour, 508, 509
- $E_{\max}$  model, 87
- EM algorithm, 171
- Empirical distribution, 46, 164, 502, 509, 513, 514
- Endemic, 124
- Environmental forcing, 136
- Epidemic, 124, 136
- Epidemiology, 98, 124, 141, 142, 548  
  spatial, 97, 98
- Episodic hormone data, 527
- Episiotomy, 67, 69
- Escalation designs, 8
- Escalation with overdose control, 6, 10
- Essential newborn care (ENC), 69
- Estimating equation, 511  
  generalized, 75, 507  
  robust, 507, 508  
  truncated, 507
- Estimating equation-based method, 142
- Expectation maximization (EM), 353, 375
- Exponential  
  covariance function, 114  
  decay, 114, 529  
  model, 505
- Exposure-response relationship, 548
- Extracorporeal membrane oxygenation (ECMO), 46, 62, 64
- Failure time  
  accelerated, 160, 386  
  data, 160  
  within-subject, 506
- False discovery rate (FDR), 314, 330, 341, 473
- False positive, 68
- Family-wise error rate (FWER), 342, 473
- First breath trial, 69
- Fisher information, 134, 145, 148, 151
- Fisher's exact test, 21
- Fisher's transformation, 71
- Fixed-width confidence interval, 60, 63  
  for partial sequential sampling, 61  
  sequential, 61
- Fluoxetine trial, 46, 520
- Frailty regression model  
  univariate proportional hazards, 159
- Frequentist  
  approach, 22  
  design, 18, 28  
  error rates, 22  
  methods, 18, 19, 20, 26, 27, 28  
  paradigm, 18
- Full conditional, 88
- Functional model, 142
- Gamma frailty model, 171
- Gap-time survival function, 506, 507
- Gateaux  
  derivative, 503  
  differentiable, 503, 504
- Gaussian process  
  infinite dimensional, 168  
  zero-mean, 165, 507, 529
- Gaussian random field, 114
- Gehan-Wilcoxon test statistic, 42
- Gene-environment interaction, 399, 405
- Gene expression. *See* Microarrays
- Generalized cross-validation (GCV), 538, 539
- Generalized estimating equations, 75, 507
- Generalized Friedman urn (GFU), 35, 36
- Generalized least-square, 75
- Generalized Polya's urn (GPU), 35, 36, 38
- Genetic shift, 124
- Genotypic, 85
- Geostatistics, 107, 108, 109, 110
- Geostatistical prediction, 119
- Gezmu-Flournoy group procedure, 7
- Gibbs sampler, 89, 532
- GML, 538
- Goodman-Karsch rule, 529
- Goodness of fit, 135, 509  
  Bayesian  $\chi^2$  statistic, 537
- Gradient matching, 125
- Graft-versus-host disease (GVHD), 177
- Graph theoretic model, 422
- Grouping error, 143
- Group randomized trial, 67
- Group-sequential, 59

- HAART, 83, 86, 87
- Hamiltonian depression scale, 46
- Haplotype, 410
- Hardy-Weinberg equilibrium, 405, 489
- Hazardous waste, 97
- Hazard function
  - baseline, 159, 160
  - baseline integrated, 162
- Hazard rate, 548
- Heatmap, 330, 372, 458
- Heavy-tailed
  - data, 507
  - distribution, 507
- Hellinger deviance test, 509
- Hellinger distance, 509, 510, 512
- Heterogeneous
  - Poisson process, 102
  - process, 100
- Hierarchical model
  - Bayesian nonlinear, 87
  - for spatial prediction, 108
- HIV, 33, 83, 84, 87, 89, 91, 92, 93, 124, 519
  - dynamic model, 84, 85
- Hormonal time series data, 527
- Hormone, 527, 528
  - decay rate of, 534
  - elimination of, 528
  - half-life of, 534
  - plasma concentration of, 528
  - pulsatile data, 528
- Hormone secretion
  - basal, 530
  - episodic, 527, 528
  - pulsatile, 530
  - rhythmic, 527, 528
- Host species, 124
- Hyperprior, 88
- Hyperparameters, 88, 89, 90, 92
  
- Identifiability, 94, 118
- Illness-death model, 506
- Ill-posed problem, 528, 531
- Image plot, 116
- Immunity, 123, 130
- Incidence, 97, 98
  - cancer, 549
  - cholera, 97
  - rate, 548
  - yellow fever, 97
- Indinavir (IDV), 86, 87, 91, 92
- Infection, 123, 130, 136
  - human-to-human, 131
- Infectious diseases, 124
- Inflated degrees of freedom (IDF), 538, 539
- Influence function, 502, 503, 504, 505, 510, 511
- Instrumental variable, 142
- Intensity
  - nonparametric estimates, 100
  - of a spatial Poisson process, 99, 100
- Intensity function, 100, 101
  - heterogeneous, 100
  - kernel-based estimates, 100
  - spatial, 119
- Interaction
  - crossover, 507
  - qualitative, 507
- Intercluster correlation, 68
- Intergene correlations. *See* Microarrays
- Interim analysis, 17, 19, 21, 22, 24
- Intracluster correlation, 68, 70, 73, 75
- Intraclass correlation (ICC), 68, 69, 70, 71, 72, 73, 74, 75
- Inverse binomial
  - trial, 58
  - two-sided test, 57
- Inverse problem, 528
- Inverse sampling, 55, 59, 60, 62, 63
  - binomial, 56, 57, 58, 63
  - for multitreatment clinical trial, 63
  - in adaptive designs, 62
  - normal, 63
  - two-sample randomized, 59
- Isotonic
  - designs, 6, 9, 11, 12
  - estimates, 9, 11
- Isotropy, 108, 109, 117
- Iterated filtering, 129
- Iterative convex minorant algorithm, 162
- Iteratively reweighted least squares
  - for maximum likelihood, 509
  
- Kaplan-Meier estimate, 513, 515, 516
- Kernel-based
  - approaches, 119
  - intensity function estimate, 100
  - smoothing methods, 100, 107, 516

- Kernel
  - density estimate, 102, 513, 516, 517
  - estimate, 101, 105
  - function, 101
- Kriging, 108, 111, 112
  - Bayesian, 112, 113, 117
  - classical, 113, 117, 118
  - equations, 110, 113, 117
  - log-Gaussian, 118
  - trans-Gaussian, 118
  - variance, 111
- Kullback-Leibler divergence, 514
- L1 norm, 162
- $L_2$  distance, 514
- Lagrangian multiplier, 111
- Latent
  - Gaussian variable, 146
  - random field, 114
  - variable, 149
- Lead time, 507
- Least absolute deviation, 166
- Least squares, 166
  - iteratively reweighted partial, 506
  - ordinary, 111
  - weighted, 111
- Lebesgue measure, 518
- Length-biased sampling, 507
- Leverage, 508
- Lifespan study, 151
- Likelihood, 23, 24, 118, 125, 126, 127, 128, 132, 166, 503
  - empirical, 162, 171
  - hierarchical, 118
  - local, 128
  - profile, 134, 162
  - profile log, 134, 166
  - ratio test, 509
  - score equation, 510
  - semiparametric, 166
  - sliced, 132, 133
  - sliced log, 133
  - weighted, 509, 510, 511, 512, 513, 520
- Likelihood-based
  - adjustment, 142
  - analysis, 125
  - inference, 125, 126
  - methods, 142
  - model comparison, 136
- Likelihood ratio, 105
  - local, 105
- Linear model
  - generalized, 142, 507, 508
  - mixed-effects, 75
- Linear prediction
  - of Gaussian data, 108
- Linear rank test, 42
- Link function, 49, 144
  - logit, 144, 145
  - probit, 144, 145
- Link-function-based design, 43, 63
- Lipschitz class of functions, 165
- Lipschitz continuous, 165
- Logistic regression, 74, 75, 145, 405, 508, 509, 510, 521
  - prospective, 508
- Log-linear model, 125
- Log-rank statistic, 42
- Longitudinal
  - data, 75, 507
  - response, 49
- Malaria, 124
- Mallows class, 508
- Mann-Whitney
  - scores, 60
  - statistics, 59, 60
- Marginal
  - distribution, 127
  - posterior distribution, 534
- Markov chain, 132
  - aperiodic, 6
  - continuous-time, 131
  - irreducible, 6
  - Monte Carlo (MCMC), 84, 89, 90, 92, 108, 112, 113, 117, 118, 126, 167, 534, 536, 543
  - Monte Carlo with birth-death (BDMCMC), 532
  - Monte Carlo with reversible jump (RJMCMC), 532, 533
  - recurrent, 6
- Markov chain designs
  - stationary distribution for, 6
- Markov process, 41
  - continuous-time, 132
  - continuous-sample-path, 132
  - partially observed, 126

- Markov process (*Continued*)  
 non-Gaussian, 132  
 unobserved, 126
- Mass spectrometry, 420, 465
- Matched-pair design, 71
- Maximum a posteriori (MAP), 535, 537
- Maximum entropy model (MEM), 445
- Maximum likelihood, 71, 111, 128, 354, 374, 406, 502, 508  
 estimator (MLE), 58, 115, 125, 128, 129, 134, 145, 147, 150, 165, 170, 502, 503, 508, 510, 515, 516, 518  
 inference, 159  
 misclassification estimate, 508  
 nonparametric estimation, 171  
 restricted, 111  
 semiparametric estimation, 162, 164, 170, 171  
 score equation, 503, 509, 511, 515
- Maximum tolerated schedule, 12
- Mean integrated squared error, 103
- Mean squared prediction error (MSPE), 109, 110, 111, 118
- Measurement error, 87, 90, 136, 141, 145, 146, 147, 148, 151, 152, 153, 425  
 in binary regression, 142  
 in covariates, 142, 144, 147, 149, 150, 152  
 in predictors, 143  
 linear, 141, 142  
 model, 141, 142  
 nondifferential, 144, 146  
 nonlinear, 142
- Mechanistic model, 136, 550  
 multi-hit, 550  
 one-hit, 550
- Median inhibitory concentration, 85, 86, 87
- M-estimator, 502, 503, 505, 508, 509, 520  
 based on Huber's  $\psi$  function, 520  
 of location, 503  
 of regression, 503  
 power-robust, 507  
 semiparametric, 166
- Metropolis-Hastings algorithm, 89, 532, 167
- Meta-analysis, 74, 319, 325, 508
- Michigan ECMO trial, 46
- Microarrays  
 array comparative genomic hybridization (aCGH), 385, 400  
 biomarker identification, 309  
 censored survival phenotypes, 351, 385  
 classification, 327  
 clustering, 328, 365  
 correlated gene expression, 309, 327, 341  
 differential expression (DE), 314, 328, 336, 341  
 meta analysis, 319, 325  
 normalization, 344  
 single nucleotide polymorphism (SNP), 385, 400  
 timecourse experiments, 309, 315, 377
- Minimum-disparity  
 estimating equation, 510  
 estimator, 510
- Minimum-distance procedure, 505, 509
- Minimum-divergence  
 estimator (MDE), 515, 516
- Minimum spanning trees, 106
- Minimum-variance unbiased estimator, 58, 504
- Minimum-volume confidence  
 rectangle, 167
- Misclassification, 141, 143, 147, 148, 149, 151, 152, 508  
 maximum-likelihood estimate, 508
- Missing  
 proportion, 153  
 response, 152
- Misspecified likelihood estimation, 166
- Mixed-effect model  
 Bayesian nonlinear, 84  
 hierarchical nonlinear, 84, 92  
 nonlinear, 92  
 nonlinear partial spline, 529, 530, 537
- Mixed model, 507
- Mixture model, 342, 365
- Mixture of Dirichlet processes (MDP), 535
- Model comparison  
 likelihood-based, 136
- Model fitting, 508
- Model free designs, 12
- Model selection, 125, 529
- Modified play-the-winner, 36
- Monte Carlo, 99, 126, 132  
 error, 133  
 p value, 105, 106  
 randomness, 128  
 sequential (SMC), 126, 127, 128, 129, 136  
 simulation, 71

- test, 105
- variability, 134
- Mortality, 131, 135, 151, 152, 513
- MRPW, 34, 38
- MTD, 7, 8, 9, 10, 11, 12
- Multicenter clinical trials, 507
- Multilevel modeling, 75
- Multinomial, 76
- Multiple comparison, 105
- Multiple testing. *See* FDR, FWER
- Multiprocess dynamic linear model, 529
- Multistage, 20
- Multistage model
  - Armitage-Doll, 552
  - linearized (LMS), 550
- Multistate events data, 506
- Multitreatment trials, 11
- Multivariate calibration model, 506
- Multivariate failure data
  - ordered, 506
- Mutations
  - drug-resistant, 85, 87
  - resistant, 85, 86
- Nakamura method, 142
- Negative binomial, 56, 59
- Negative exponential
  - disparity, 510
- Neonatal mortality rate, 67
- Neonatal resuscitation program (NRP), 69
- Neyman allocation, 44
- NMPSM, 538, 539, 540, 542
- Noncompliance, 83, 94
- Nonlinear forecasting, 125
- Non-Markov transition, 506
- Nonparametric
  - approach, 507
  - methods, 506
  - model, 502
  - regression, 134, 142
  - smoothing, 513
  - statistics, 501, 502, 506
- Normal
  - approximation, 22
- Normalization, 344, 471
- Nugget, 111, 114
- Observation process, 126
- Observation space, 126
- Oceanographic science, 136
- Odds ratio, 26, 74, 405
  - family, 159
  - log, 75
  - model for right-censored data, 161
  - transformation, 159
- Oncology, 11, 16, 26, 27
- Operating characteristics, 46
- Optimal adaptive design, 43
- Optimal allocation rule, 44
- Ordered groups, 11
- Ordered probit model, 152
- Ordinal, 11, 76, 152
- Ordinal categorical scale, 41
- Pandemic, 130
- Panel data, 160
- Partial sequential, 62
  - design, 59
  - sampling, 58
- Pathogenesis, 83
- Pathogen species, 124
- P-Donsker, 163, 164
- Penalization, 386, 421, 459, 528
- Penalized likelihood estimation, 166, 168
- Penalized maximization, 162
- Pearson residual, 510, 511
- Permutation, 319, 320, 357
  - test, 74
- Persistent pulmonary hypertension of the
  - newborn (PPHN), 62
- Perspective plot, 116
- Perturbation, 141, 504, 505
  - random, 132
- P-Glivenko-Cantelli, 163, 164
- Pharmacokinetics, 83, 84, 87, 90, 92
- Phase I trials, 16, 23, 45, 91
- Phase II, 15, 16, 17, 18, 19, 21, 23, 24, 25, 26, 27, 28, 91
- Phase III, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 33, 49
- PhenoSense HIV, 92
- Phenotype assays, 87
- Phenotypic
  - marker, 85, 90, 92
  - tests, 85
- Plasma concentration-time curve
  - area under, 87

- Play-the-winner (PW), 34, 38, 46, 63  
 randomized (RPW), 34, 35, 37, 38, 39,  
 40, 41, 46, 48, 49, 62, 63
- Poisson  
 process (homogeneous spatial), 99  
 process (heterogeneous spatial), 100  
 random variable, 99  
 regression models (spatial), 99
- Poisson process, 163  
 heterogeneous, 102  
 heterogeneous spatial, 100  
 homogeneous spatial, 99  
 first-order (mean) properties of, 100  
 second-order properties of, 100
- Polya urn (Polya-Eggenberger urn), 35  
 generalized (GPU), 35, 36, 38  
 randomized (RPU), 36, 37, 38
- Population dynamics, 124, 131
- Population models, 123, 124, 125, 128  
 continuous-state, 131  
 deterministic, 124  
 discrete-state, 131  
 mechanistic, 124  
 phenomenological, 124  
 stochastic, 124
- Posterior, 49  
 distribution, 23, 24, 89, 112, 113,  
 114, 118  
 kernel estimate of, 114  
 mean, 115, 116  
 median, 115  
 mode, 115  
 predictive distribution, 89, 113, 116, 117  
 predictive expectation, 113  
 predictive mean, 116, 117  
 probability, 24, 25
- Postherpetic neuralgia, 47
- Postpartum hemorrhage, 67
- Power, 18, 22, 43, 44, 55, 60, 106, 507
- Power law, 422
- Prediction credible interval, 92, 93
- Predictive density/distribution, 49, 90  
 conditional, 89  
 local variance of, 116  
 mean of, 116
- Predictive variance, 116
- Pregabalin trial, 47
- Prevalence, 97, 98, 123
- Princeton robustness study, 502
- Principal-component regression  
 robust, 506
- Principal components analysis (PCA), 369,  
 393, 396, 476
- Prior distribution, 22, 23, 24, 25, 90, 113,  
 117, 118, 125  
 conjugate, 114  
 discrete, 114  
 flat, 114  
 gamma, 88  
 inverse gamma, 533  
 inverse Wishart, 114  
 Jeffreys', 114  
 lognormal, 534  
 negative binomial, 533  
 normal, 88  
 reference, 114  
 vague, 114  
 Wishart, 88
- Prior  
 information, 94  
 parameters, 114  
 probability, 118
- Probability of disease, 548
- Profile likelihood, 134, 167, 168  
 semiparametric, 167
- Profile log likelihood, 134, 170
- Profile sampler, 166, 168
- Proof-of-concept studies, 15, 17
- Proportional odds model, 159, 169  
 for right-censored data, 160
- Prospective, 405, 508
- Protease inhibitor (PI), 83, 85, 86, 87, 90
- PULSAR, 529
- Pulse, 527, 528, 529  
 gamma-shaped, 529
- Pulsefit, 529
- Pulsatile hormone data, 528  
 criterion-based methods for, 528  
 general biophysical model for, 530  
 model-based methods for, 528
- Pure birth process  
 continuous-time, 37
- Quadratic approximation, 134, 135
- Quantal response data, 549

- R, 101  
 ASSIST library, 539  
 geoR library, 111, 114  
 KernSmooth library, 101  
 PULSE package, 539  
 splancs library, 101
- Radiation, 143, 151, 515
- Random effect model, 75, 136, 508  
 logit, 152  
 one-way, 71  
 probit, 152  
 proportional hazards regression, 169
- Random forests, 395, 444, 451
- Randomized play-the-winner (RPW), 34, 35, 37, 38, 39, 40, 41, 46, 48, 49, 62, 63, 519  
 adaptive (ARPW), 40
- Randomized Poly Urn (RPU), 36, 37, 38
- Random-walk rule, 11
- Rank-based procedures, 507
- Rapid-eye-movement latency (REML), 46
- Receiver operating characteristic (ROC)  
 curve, 343, 397, 445, 448, 449
- Recording error, 143
- Recurrent events, 506
- Regression  
 additive hazards, 160  
 binary, 144, 152  
 bivariate binary, 146  
 bivariate isotonic, 11  
 logistic, 74, 75, 145, 405, 508, 509, 511  
 nonparametric, 134, 142  
 prospective logistic, 508
- Regularization. *See* Penalization
- Regular parameter, 160, 165
- Remote sensing, 119
- Renewal theory, 57, 58
- Repeated-events data, 506
- Resampling, 127  
 systematic, 127
- Reservoir, 130, 131
- Residual  
 standardized prediction, 135
- Residual adjustment function (RAF), 510, 511, 512  
 Hellinger, 513  
 negative exponential, 513
- Response-adaptive  
 designs, 34, 49  
 trial, 47
- Retrospective, 123, 405, 508
- Reverse transcriptase inhibitor (RTI), 83, 85, 86, 87
- Rheumatoid arthritis, 46
- RIC, 538, 539
- Risk, 98  
 attributable, 105  
 background, 106  
 of disease, 100  
 local relative, 105  
 log relative, 102, 103, 104, 105, 106, 107  
 relative, 102, 105
- Ritonavir (RTV), 86, 87, 91, 92
- RNA, 91, 92, 93
- Robust/robustness, 103, 119, 501, 502, 503, 505, 506, 507, 508, 509, 511, 512, 515, 519, 520, 521  
 adaptive methods in clinical trials, 518  
 B-, 502  
 estimating equations, 507, 508  
 infinitesimal approach to, 503  
 minimax approach to, 502, 503  
 qualitative, 502  
 quantitative, 502
- Rosenberg-Stallard-Ivanova-Harper-Ricks (RSIHR) rule, 44, 48
- RPW( $\alpha, \beta$ ), 35, 44
- Sampling  
 inverse, 55, 59, 60, 62  
 inverse binomial, 56, 57, 58, 63  
 inverse normal, 63  
 partial sequential, 58  
 “Sandwich” variance estimator, 75
- SaTScan, 105, 106
- Scan statistic, 105, 107  
 circular, 107  
 spatial, 105
- Screening study, 22
- Seasonal transmissibility, 135
- Seasonality, 136
- Semi-competing risks problem, 177
- Semiparametric, 159, 352, 405, 474, 507  
 maximum likelihood estimation (SPMLE), 162, 164

- Semivariogram, 110, 111, 112, 113, 114, 115, 117, 118  
 empirical, 111, 112, 114  
 exponential model for, 111, 113  
 isotropic, 110  
 parametric families, 111  
 stationary, 110  
 theoretical, 111, 112
- Sensitivity analysis, 75
- Sequence data, 326, 443
- Sequential, 17, 20, 21, 22, 24, 57, 58, 62, 63  
 estimation-adjusted urn (SEU), 38  
 maximum likelihood estimation, 39, 40  
 ML design, 63  
 Monte Carlo (SMC), 126, 127, 128, 129, 136
- S-estimator, 508
- Severe acute respiratory syndromes (SARS), 124
- Signature, 327, 368, 472
- Sill, 110, 111, 114  
 posterior distribution of, 115
- Simon design, 21
- Simulated annealing, 132
- Simulation extrapolation (SIMEX), 142
- Single-arm, 20, 22, 23, 24, 25, 27
- Single nucleotide polymorphism (SNP), 385, 400, 414, 490
- Single-stage  
 design, 21  
 procedure, 22
- Single-treatment pilot study, 17
- Sliced likelihood, 132, 133, 134  
 plot, 132, 133
- Smoothing, 347, 471, 490  
 kernel-based, 100  
 parameter, 101
- Sobolev space, 162
- Spanning trees  
 minimum, 106
- Spatial  
 cluster, 119  
 correlation, 98, 99, 108, 110  
 covariance, 108, 110, 114  
 data, 98  
 density function, 100, 102  
 epidemiology, 97, 98, 107, 108, 118, 119  
 information, 98  
 intensity function, 119  
 pattern, 98, 99, 100, 116  
 point pattern, 98, 100  
 point process, 99, 107, 119  
 Poisson process, 99, 100, 119  
 Poisson regression models, 99, 119  
 prediction, 98, 107, 108, 109, 113, 117, 119  
 random field, 113  
 scan statistic, 105, 106  
 statistics, 97, 117  
 trend, 98
- Spatiotemporal  
 data, 136  
 model, 136  
 problem, 136  
 variability, 136
- Spending function method, 21
- Standardized prediction residuals, 135
- State process, 126, 127
- State space, 126
- State space model (SSM), 125, 126, 132, 134, 135, 136  
 Gaussian, 125  
 linear, 125  
 nonlinear, 125, 126
- Stationarity, 108, 117
- Stationary distribution, 128  
 for Markov chain designs, 6  
 of dose assignments, 6
- Stationary point equation, 162
- Statistical functional, 502
- Stochastically smaller, 60
- Stochastic differential equation model, 529
- Stochasticity  
 demographic, 124, 131  
 environmental, 124, 131
- Stochastic optimization  
 Robbins-Monro type, 128
- Stopping rule/criterion, 24, 57, 58, 59, 519
- Stratified design, 71
- Strongly consistent, 60
- Structural model, 132, 142
- Success-driven design, 62
- Sufficiency, 502
- Supervised learning. *See* Classification

- Support vector machine (SVM), 454
- Surrogate, 141, 143, 144, 146, 148, 149, 150, 152
- Survival analysis, 159, 506
- Survival curve, 507, 513
- Survival data
  - case-cohort estimators of, 507
  - censored, 508
  - doubly censored, 169
- Survival function, 161
  - baseline, 159
- Survival model
  - semiparametric, 159
- Susceptible, 124, 130
- Susceptible-Infected-Removed (SIR), 124
  
- Taylor series, 125
- T cells, 85
- Thall-Simon design, 24
- Thomas-Hultquist procedure, 71
- Thymus, 85
- Timecourse experiment. *See* Microarrays
- Time-series, 135, 136
  - data, 124
  - hormonal data, 527
  - models, 125
- Time-to-event, 10, 76
- Time-to-event models
  - general product hazards models, 552
  - log-linear models, 552
  - multi-event models, 552
  - relative and additive risk models, 552
- Time-varying, 84, 85, 87
  - coefficient model, 160
- TITE-CRM, 10
- Tolerance distribution model, 549
  - log-probit, 550
  - logit, 550
  - normal (probit), 549
- Tobler's first law of geography, 107
- Toxicity, 26
  - rate, 7, 8, 9
  - monotonicity, 12
- Toxicology, 512, 548
- Transcription factor binding sites, 377, 443
- Transformation invariance, 125
- Transformation model, 159
  
- Transmissibility, 135
  - seasonal, 135
- Transmission, 123
  - human-to-human, 130
  - vertical, 519
- Treatment effect
  - mapping, 41, 42
  - models, 84, 85
- Trimmed mean, 505, 507
- Two-stage
  - design, 21
  - procedure, 22, 508
- Type I error, 18, 19, 20, 21, 22, 26, 27, 28
- Type II error, 18, 19, 21, 26
  
- ULTRA, 529
- Unbiasedness, 118
- Uniformly most powerful (UMP), 56
  - unbiased, 57
- Unimodal prior, 23
- Unit of analysis error, 68
- United States Environmental Protection Agency (USEPA), 108
- Unsupervised learning. *See* Clustering
- Up-and-down designs
  - Markovian, 6
  - Markovian-motivated nonparametric, 6
  - Markovian group, 8
- Upper level set approach, 106
- Utility function, 25
  
- Variance components, 75, 131
- Variance-covariance matrix, 110, 114
  - positive definite, 110
- Variance inflation factor, 72, 74
- Variation
  - between-subject, 88
  - within-subject, 88
- Variogram, 117
- Variography, 111
- Vibrio cholerae*, 130, 135
- Viral
  - dynamics, 84, 86, 87, 89
  - load, 83, 84, 87, 89, 90, 91, 92, 94
  - rebound, 90, 92, 94
- Virion, 85
- Virological marker, 83

- Weibull, 515
  - MLE fit, 516, 517
  - model, 550
  - robust (MDE) fit, 516, 517
  - two-component mixture, 516, 517, 518
- White noise
  - Gaussian, 132
- Wilcoxon-Mann-Whitney, 42, 43
- Winsorized mean, 505
- Within-cluster correlation, 68, 69
- Within-cluster variance, 73
- Yeast two-hybrid (Y2H), 325, 419
- Yellow fever, 97
- Zidovudine, 33, 519
- Zoonotic, 124